Compare Docusign Inc (DOCU) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Docusign Inc trades at $70.88 (market cap $13.35B), while Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B). The key difference: Docusign Inc and Halozyme Therapeutics Inc. Common Stock are close in size by market cap, and Docusign Inc is more actively traded (3,158,858 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| DOCU | HALO | |
|---|---|---|
Market Cap | $13.35B | $12.58B |
Volume | 3,158,858 | 2,179,278 |
Sector | Technology | Health |
52-Week High | $73.14 | $115.22 |
52-Week Low | $41.75 | $61.63 |
Typical Hold Time | 71 Days | 1 Days |
Enterprise Value | $12.76B | $14.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.08, up 3.16% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is solid, and profitability metrics like net income margin and ROE show significant improvement. Recent news highlights AI integration in contract processing and leadership in workflow software, though insider selling has been noted.
The outlook for DOCU is positive, driven by earnings beats and AI adoption, but risks include valuation concerns with a P/E of 43.55 and insider selling. The consensus price target of $68.75 suggests limited upside from current levels, indicating a cautious stance from analysts despite bullish technical signals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
